1. Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta.
- Author
-
Cairoli R, Beghini A, Turrini M, Bertani G, Nadali G, Rodeghiero F, Castagnola C, Lazzaroni F, Nichelatti M, Ferrara F, Pizzolo G, Pogliani E, Rossi G, Martinelli G, and Morra E
- Subjects
- Adolescent, Adult, Age Factors, Core Binding Factor beta Subunit genetics, Female, Follow-Up Studies, Gene Expression, Humans, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute therapy, Leukocyte Count, Leukocytes pathology, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins c-kit blood, Proto-Oncogene Proteins c-kit genetics, Sex Factors, Survival Analysis, Antineoplastic Agents therapeutic use, Core Binding Factor beta Subunit blood, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute diagnosis
- Abstract
Acute myeloid leukemia (AML) with deranged core-binding factor beta (CBFβ) is usually associated with a favorable prognosis with 50-70% of patients cured using contemporary treatments. We analyzed the prognostic significance of clinical features on 58 patients with CBFβ-AML aged ≤60 years. Increasing age was the only predictor for survival (P <0.001), with an optimal cut-point at 43 years. White blood cells (WBCs) at diagnosis emerged as an independent risk factor for relapse incidence (P = 0.017), with 1.1% increase of hazard for each 1.0 × 10(9) /L WBC increment. KIT mutations lacked prognostic value for survival and showed only a trend for relapse incidence (P = 0.069)., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF